Back


22/05/2020
Orphazyme’s arimoclomol receives US Fast Track Designation in Amyotrophic Lateral Sclerosis
Copenhagen, Denmark, May 22, 2020 – Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, announces that the Company has received Fast Track Designation from the US Food and Drug Administration (FDA) for the development of arimoclomol for the treatment of Amyotrophic Lateral Sclerosis (ALS).

Download the pdf file





X

X